Format

Send to

Choose Destination
Ann Thorac Surg. 2016 Jun;101(6):2102-11. doi: 10.1016/j.athoracsur.2016.01.033. Epub 2016 Apr 12.

Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.

Author information

1
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri.
2
Department of Radiation Oncology, Washington University in St. Louis, St. Louis, Missouri.
3
Division of Medical Oncology, Washington University in St. Louis, St. Louis, Missouri.
4
Department of Pathology and Immunology, Washington University in St. Louis, St. Louis, Missouri.
5
Division of Cardiothoracic Surgery, St. Luke's Hospital, Chesterfield, Missouri.
6
Division of Cardiothoracic Surgery, Washington University in St. Louis, St. Louis, Missouri. Electronic address: crabtreet@wustl.edu.

Abstract

BACKGROUND:

Although studies have suggested standard therapy for clinical T2N0 esophageal cancer should be primary surgery, we hypothesize there is a subgroup for whom induction therapy may result in improved overall survival.

METHODS:

Patients with cT2N0 esophageal cancer receiving induction therapy or upfront esophagectomy (UE) were identified in the National Cancer Data Base. The UE patients were dichotomized as (1) pathologically upstaged, or (2) same-staged or downstaged. Logistic regression models identified variables associated with upstaging, and Kaplan-Meier analysis compared median overall survival.

RESULTS:

From 2006 to 2012, 932 cT2N0 patients (52.2%) received UE, and 853 (47.8%) received induction therapy first. In all, 326 of 713 UE patients (45.7%) were upstaged: 87 of 326 (26.7%) had T upstaging; 98 of 326 (30.1%) had N upstaging; and 141 of 326 (43.3%) had both. Patients upstaged after UE had a higher tumor grade (35.1% versus 57.1% grade 3), and a higher rate of lymphovascular invasion (57.1% versus 17.7%; both p < 0.001). Variables associated with upstaging included lymphovascular invasion (odds ratio 6.0, 95% confidence interval: 2.9 to 12.5, p < 0.001) and tumor grade 3 (odds ratio 9.4, 95% confidence interval: 1.8 to 48.4, p = 0.007). Of upstaged UE patients, only 144 (44.2%) received adjuvant therapy. The median overall survival for cT2N0 patients upstaged after UE was 27.5 ± 2.5 months versus 43.9 ± 2.9 months for induction therapy patients (any resultant pathologic stage, p < 0.001).

CONCLUSIONS:

Half of all cT2N0 patients were pathologically upstaged after UE, with worse survival compared with patients receiving induction therapy. Refining an upstaging model would help select patients for induction therapy and increase the rate of chemotherapy in patients at risk for systemic disease.

PMID:
27083246
PMCID:
PMC5103634
DOI:
10.1016/j.athoracsur.2016.01.033
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center